WO2022173047A1 - 体温低下剤、体温上昇抑制剤、体温低下用食品組成物、及び体温上昇抑制用食品組成物 - Google Patents
体温低下剤、体温上昇抑制剤、体温低下用食品組成物、及び体温上昇抑制用食品組成物 Download PDFInfo
- Publication number
- WO2022173047A1 WO2022173047A1 PCT/JP2022/005738 JP2022005738W WO2022173047A1 WO 2022173047 A1 WO2022173047 A1 WO 2022173047A1 JP 2022005738 W JP2022005738 W JP 2022005738W WO 2022173047 A1 WO2022173047 A1 WO 2022173047A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- body temperature
- orotic acid
- food composition
- lowering
- suppressing
- Prior art date
Links
- 230000036760 body temperature Effects 0.000 title claims abstract description 104
- 235000013305 food Nutrition 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims abstract description 153
- 229960005010 orotic acid Drugs 0.000 claims abstract description 74
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 35
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 12
- 230000036757 core body temperature Effects 0.000 claims description 45
- 239000003112 inhibitor Substances 0.000 claims description 13
- 230000000694 effects Effects 0.000 description 26
- 238000000034 method Methods 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 230000002631 hypothermal effect Effects 0.000 description 11
- 150000007513 acids Chemical class 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000000284 resting effect Effects 0.000 description 10
- 206010021113 Hypothermia Diseases 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 206010019345 Heat stroke Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- -1 alkali metal salts Chemical class 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008925 spontaneous activity Effects 0.000 description 4
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 3
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- ZWIADYZPOWUWEW-XVFCMESISA-N CDP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-XVFCMESISA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- CYDYNVMCEGXBEM-JXOAFFINSA-N TDP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 CYDYNVMCEGXBEM-JXOAFFINSA-N 0.000 description 2
- IGWHDMPTQKSDTL-JXOAFFINSA-N TMP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IGWHDMPTQKSDTL-JXOAFFINSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 2
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- UJLXYODCHAELLY-XLPZGREQSA-N dTDP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 UJLXYODCHAELLY-XLPZGREQSA-N 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- QHWZTVCCBMIIKE-SHYZEUOFSA-N dUDP Chemical compound O1[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 QHWZTVCCBMIIKE-SHYZEUOFSA-N 0.000 description 2
- JSRLJPSBLDHEIO-SHYZEUOFSA-N dUMP Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 JSRLJPSBLDHEIO-SHYZEUOFSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000017525 heat dissipation Effects 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 238000009220 hypothermia therapy Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 201000002638 post-cardiac arrest syndrome Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical class C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- YXUZGLGRBBHYFZ-UHFFFAOYSA-N 2,4-dioxo-1h-pyrimidine-6-carboxylic acid;hydrate Chemical compound O.OC(=O)C1=CC(=O)NC(=O)N1 YXUZGLGRBBHYFZ-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- PGAVKCOVUIYSFO-UHFFFAOYSA-N [[5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical class NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- UFIVEPVSAGBUSI-UHFFFAOYSA-N dihydroorotic acid Chemical compound OC(=O)C1CC(=O)NC(=O)N1 UFIVEPVSAGBUSI-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000006266 hibernation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- FKCRAVPPBFWEJD-XVFCMESISA-N orotidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1C(O)=O FKCRAVPPBFWEJD-XVFCMESISA-N 0.000 description 1
- FKCRAVPPBFWEJD-UHFFFAOYSA-N orotidine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1C(O)=O FKCRAVPPBFWEJD-UHFFFAOYSA-N 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000012461 sponges Nutrition 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Definitions
- the present invention relates to a body temperature lowering agent, a body temperature rise suppressing agent, a body temperature lowering food composition, and a body temperature rise suppressing food composition.
- Orotic acid is a precursor for pyrimidine nucleotide synthesis and is contained in dairy products such as milk. Although orotic acid is sparingly soluble in water, a production method for using it as a drink that is difficult to precipitate is known (Patent Document 1, etc.). In addition, orotic acid is used in second-class pharmaceuticals, third-class pharmaceuticals, quasi-drugs, health foods, etc. for the purpose of nutritional tonic, promotion of liver function, and cosmetic effects.
- Non-Patent Document 1 uric acid level lowering action
- Patent Document 2 oxygen consumption and energy consumption reducing action
- Patent Document 4 endurance improving action
- External peripheral cooling such as wearing ice vests, pre-cooling and ice slurry beverages, which are known conventional methods of controlling hyperthermia, require specialized equipment, their wearing interferes with activity, and large volumes of food are consumed. Despite the need for water, the cooling effect does not reach deep inside the body and does not last long.
- An object of the present invention is to provide a hypothermia agent, a hypothermia inhibitor, and a food composition for hypothermia, which can spontaneously and continuously lower body temperature and suppress an excessive rise in body temperature without the need for a device. , and to provide a food composition for suppressing an increase in body temperature.
- orotic acid has the effect of lowering the core body temperature at rest and suppressing an excessive increase in body temperature during exercise, and provides a body temperature lowering agent, a body temperature increase inhibitor, a body temperature lowering food composition, and found that it is useful as a food composition for suppressing an increase in body temperature, and completed the present invention.
- the present invention includes the following aspects.
- a hypothermic agent containing, as an active ingredient, at least one substance selected from the group consisting of orotic acid, derivatives thereof, and salts thereof.
- a body temperature rise suppressing agent containing, as an active ingredient, at least one substance selected from the group consisting of orotic acid, derivatives thereof, and salts thereof.
- the food composition of [7] or [8], wherein the body temperature is core body temperature.
- a hypothermia agent, an agent for suppressing an increase in body temperature, and a food composition for hypothermia are capable of spontaneously and continuously lowering body temperature and suppressing an excessive increase in body temperature without the need for a device. , and a food composition for suppressing an increase in body temperature can be provided.
- Fig. 2 shows changes in resting core body temperature in a vehicle-administered group, a 30 mg/kg orotic acid-administered group, and a 300 mg/kg orotic acid-administered group.
- "***" indicates that the orotic acid 300 mg / kg administration group has a p value of less than 0.1% with respect to the vehicle administration group
- "$$" is orotic acid 300 mg / kg
- the administration group shows that the p value is less than 1% for the orotic acid 30 mg / kg administration group
- "$$" is the orotic acid 300 mg / kg administration group, the orotic acid 30 mg / kg administration group , the p-value is less than 0.1%.
- FIG. 4 shows resting heart rate changes in a vehicle administration group, a 30 mg/kg orotic acid administration group, and a 300 mg/kg orotic acid administration group.
- Fig. 2 shows changes in resting heat production in a vehicle-administered group, a 30 mg/kg orotic acid-administered group, and a 300 mg/kg orotic acid-administered group.
- "*" indicates that the p-value of the 300 mg/kg orotic acid administration group is less than 5% of the vehicle administration group.
- FIG. 3 shows spontaneous activity at rest in a vehicle administration group, a 30 mg/kg orotic acid administration group, and a 300 mg/kg orotic acid administration group.
- FIG. 2 shows changes in core body temperature during and after exercise in a vehicle-administered group and in a 300 mg/kg orotic acid-administered group.
- “Exercise” indicates the time (minutes) of treadmill exercise.
- “*” indicates that the p-value of the 300 mg/kg orotic acid administration group is less than 5% of the vehicle administration group.
- Fig. 2 shows changes in heart rate during and after exercise in a vehicle-administered group and in a 300 mg/kg orotic acid-administered group.
- “Exercise” indicates the time (minutes) of treadmill exercise.
- Fig. 2 shows changes in heat production during and after exercise in a vehicle-administered group and a 300 mg/kg orotic acid-administered group.
- “Exercise” indicates the time (minutes) of treadmill exercise.
- “*” indicates that the p-value of the 300 mg/kg orotic acid administration group is less than 5% of the vehicle administration group.
- Figure 2 shows exercise economy in a vehicle-administered group and in a 300 mg/kg orotic acid-administered group.
- "**" indicates that the 300 mg/kg orotic acid administration group has a p value of less than 1% with respect to the vehicle administration group.
- the body temperature-lowering agent of the present invention contains at least one substance selected from the group consisting of orotic acid, derivatives thereof, and salts thereof (hereinafter collectively referred to as "orotic acids"). Contains as an ingredient.
- the body temperature rise inhibitor of the present invention contains at least one substance selected from the group consisting of orotic acids as an active ingredient.
- orotic acid is also referred to as orotic acid, orotic acid, and uracil 6-carboxylic acid.
- the orotic acid in the present invention includes both the free orotic acid (free form) and the orotic acid hydrate, but the free form (free form) of orotic acid is preferred.
- the derivative of orotic acid is not particularly limited as long as it can be derived from orotic acid and has an effect of lowering body temperature and suppressing an increase in body temperature.
- Examples include dihydroorotic acid, orotidyl acid, orotidine.
- the salt of the orotic acid salt and the salt of the orotic acid derivative is preferably a salt that is acceptable as a food or pharmaceutical product.
- alkali metal salts such as sodium salts and potassium salts, calcium salts, magnesium salts and the like Alkaline earth metal salts, heavy metal salts such as zinc salts, ammonium salts, basic amino acid salts such as arginine, amine salts such as triethylamine salts, choline salts, carnitine salts, creatine salts and the like.
- the orotic acids in the present invention may be commercially available ones, or produced and accumulated in the culture solution by fermentation methods using various microorganisms introduced with mutations of pyrimidine auxotrophy or pyrimidine analog resistance (for example, , See Japanese Patent No. 2927882), from the above-mentioned cultures and whey containing orotic acid, using a normal purification method such as a precipitation method, a chromatography method using an ion exchange resin or activated carbon, etc. Separation and purification methods such as It is also possible to use those purified and collected by
- the body temperature may be skin temperature, which is the surface temperature of the body, or core body temperature, which is the internal temperature of the body such as the brain and internal organs. It can lower core body temperature, which is the exact body temperature that is not received.
- the agent for suppressing a rise in body temperature of the present invention can suppress the rise in core body temperature.
- the hypothermia of the present invention lowers body temperature at rest. Since the body temperature-lowering agent of the present invention can lower body temperature at rest, for example, it can be actively used in patients with severe brain injury (head injury, cerebrovascular disease, post-cardiac arrest syndrome, etc.). It can be used for therapy to lower body temperature to 32-34°C (hypothermia therapy). Hypothermia is considered a treatment to minimize secondary brain damage because it can protect the brain by lowering brain metabolism. For example, resting hypothermia can be neuroprotective after a stroke attack. It is generally believed that a 1° C. decrease in brain temperature reduces brain metabolism by about 7%, and hypothermia therapy for postcardiac arrest syndrome is recognized worldwide and has become a standard treatment. In addition, the body temperature-lowering agent of the present invention lowers body temperature at rest, but can maintain a healthy state for the body. can be used. Furthermore, in the future, it is expected to be applicable to hibernation and life extension.
- the body temperature lowering action of the body temperature lowering agent of the present invention can be measured by a method of measuring core body temperature at rest.
- Resting core body temperature can be measured according to a known method, for example, the method described in Takahashi et al. (Nature 583: 109-114, 2020). Specifically, it can be measured as follows.
- a TRM54P rat telemetry system manufactured by KAHA Sciences
- SmartPad TR181: manufactured by KAHA Sciences
- the main body of the TRM54P rat telemetry system is placed in the peritoneal cavity of the test animal to perform measurement.
- the body temperature rise inhibitor of the present invention lowers body temperature during exercise. Since the body temperature rise inhibitor of the present invention can lower the body temperature during exercise, for example, it is possible to suppress the rise in body temperature during long-term endurance exercise such as marathon, and improve long-term endurance exercise capacity. can be made. Since the agent for suppressing an increase in body temperature of the present invention can also suppress an excessive increase in body temperature, it can be used for the prevention and treatment of diseases caused by an excessive increase in body temperature such as heatstroke.
- the body temperature rise inhibitory action of the body temperature rise inhibitor of the present invention can be measured by a method of measuring core body temperature during exercise.
- Core body temperature during exercise can be measured according to a known method, for example, the method described in Takahashi et al. (Nature 583: 109-114, 2020). Specifically, it can be measured as follows. Rats are placed in a small animal Redmill metabolic chamber with a 10° incline, resting core body temperature is measured for 20 minutes, and then a single drug (orotic acid) is administered intraperitoneally. Rest for 15 minutes after dosing and start exercising.
- Exercise is started at a running speed of 5 m/min, which is increased to 20 m/min over 5 minutes, and the core body temperature is measured in the same manner as the resting core body temperature measurement method. If the core body temperature during exercise is suppressed as compared with the case where orotic acids are not administered, it can be determined that they have an effect of suppressing an increase in body temperature.
- the body temperature lowering agent and body temperature rise suppressing agent of the present invention may contain only orotic acids, but may contain pharmaceutically acceptable usual carriers, antioxidants, binders, stabilizers, excipients, Various formulation ingredients such as diluents, pH buffers, disintegrants, solubilizers, solubilizers and isotonic agents may be added.
- the dosage form of the body temperature lowering agent and body temperature rise suppressing agent of the present invention may be solid formulations such as powders, granules and capsules, and liquid formulations such as solutions, emulsions and suspensions. good too.
- the method of administering the body temperature-lowering agent of the present invention is not particularly limited as long as the effect of lowering core body temperature at rest is obtained, and may be oral administration or parenteral administration, but oral administration is preferred. preferable.
- parenteral administration methods include enteral administration and intravascular administration (preferably intravenous administration).
- the dosage of the body temperature lowering agent of the present invention may vary depending on symptoms, dosage form, body weight, etc. In the case of oral administration, it is 50 mg to 10 g, preferably 50 mg to 10 g per day for an adult (about 60 kg body weight) in terms of orotic acids. It can be from 500mg to 3g.
- the administration method of the body temperature rise inhibitor of the present invention is not particularly limited as long as the effect of suppressing the rise in core body temperature during exercise is obtained, and may be oral administration or parenteral administration. , oral administration is preferred. Examples of parenteral administration methods include enteral administration and intravascular administration (preferably intravenous administration).
- the dosage of the agent for suppressing hyperthermia of the present invention may vary depending on symptoms, dosage form, body weight, etc. In the case of oral administration, it is 50 mg to 10 g, preferably 50 mg to 10 g per day for an adult (about 60 kg body weight) in terms of orotic acids. It can be from 500mg to 3g.
- Examples of subjects for administration of the hypothermic agent and antihyperthermic agent of the present invention include vertebrates, and among them, animals belonging to mammals and animals belonging to birds can be preferably exemplified. , monkeys, mice, rats, hamsters, guinea pigs, cattle, pigs, horses, rabbits, sheep, goats, cats, dogs, chickens, quails, etc., and among them, humans and livestock/poultry are more preferred. can be exemplified.
- Food composition for lowering body temperature and food composition for suppressing rise in body temperature Since orotic acids have a body temperature-lowering effect, they can be contained in various food compositions as an active ingredient of body temperature-lowering food compositions in the case of lowering body temperature at rest.
- food compositions include not only foods but also beverages.
- orotic acids have an effect of suppressing the increase in body temperature
- it is an active ingredient of a food composition for increasing body temperature for the prevention, treatment and improvement of diseases and symptoms caused by body temperature increase such as body temperature increase during exercise and heat stroke.
- food compositions include not only foods but also beverages.
- the food composition for lowering body temperature and the food composition for suppressing the increase in body temperature of the present invention include, for example, various beverages, yogurt, cheese, butter, lactic acid fermented products, and the like.
- the food composition of the present invention contains edible carbohydrates, proteins, lipids, vitamins, minerals, sugars (glucose etc.), natural or artificial sweeteners, citric acid, carbonated water, fruit juice, stabilizers and preservatives. Agents, binders, thickeners, emulsifiers and the like can be added as appropriate.
- the amount of orotic acid compounded in the food composition of the present invention is appropriately selected according to the type of food composition and the effect expected from the administration of the food composition. 0001 to 100% by mass, preferably 0.001 to 100% by mass, more preferably 0.01 to 100% by mass.
- orotic acids can be ingested in an amount of 1 mg to 10 g, preferably 10 mg to 5 g, more preferably 50 mg to 1 g per day for an adult (body weight of about 60 kg).
- the frequency of ingestion is not particularly limited, but is preferably 1 to 3 times a day, and the frequency of ingestion may be increased or decreased as necessary.
- “per day” is different depending on the form of the food composition of the present invention, but it is the recommended amount of intake per day displayed, or if it is a drink that is usually consumed at one time, it is per bottle. It refers to the amount contained.
- the above food composition may be a food composition labeled as having a body temperature lowering effect and/or a body temperature rise suppressing effect.
- Food compositions labeled as having a body temperature rise-inhibiting effect include, for example, indications that they have a body temperature rise-inhibiting effect during exercise, prevention and/or treatment of diseases caused by body temperature rise such as heat stroke, etc. Examples thereof include food compositions labeled as having an effect.
- Example 1 Effect of orotic acid on core body temperature at rest
- a one-week preliminary breeding period was provided before the day of the experiment.
- the room temperature during the experiment was maintained at 22 ⁇ 2°C.
- a telemeter TRM54P, manufactured by KAHA Sciences
- TRM54P a telemeter for measuring body temperature was placed in the peritoneal cavity, and a recovery period and an acclimatization period of one week each were provided.
- Fig. 1 shows changes in core body temperature
- Fig. 2 shows changes in heart rate
- Fig. 3 shows changes in heat production.
- FIG. 4 shows the amount of spontaneous activity.
- systolic/diastolic/mean blood pressure (not shown) increased significantly in the orotic acid administration group, and heart rate did not change, as shown in Figure 2.
- the decrease in core body temperature in rats is caused by increased heat dissipation due to suppression of metabolic thermogenesis and peripheral vasodilation.
- heat dissipation is accelerated, blood pressure decreases, and the amount of heat production measured by an expiratory gas analyzer decreases. it seems to do.
- Heart rate values also indicated that orotic acid-induced reduction in core body temperature was activity-independent. From the results of this example, it was clarified that orotic acid has the effect of suppressing heat production and lowering core body temperature.
- Example 2 (Effect of orotic acid on core body temperature during exercise) Using 10-week-old male Wistar rats, a one-week preliminary breeding period was provided before the day of the experiment. The room temperature during the experiment was maintained at 22 ⁇ 2°C. After preliminary breeding, a telemetry device (trade name: TRM54P, manufactured by KAHA Sciences) for measuring body temperature was placed in the abdominal cavity, and a running test was performed after a recovery period of one week.
- orotic acid or vehicle physiological saline
- physiological saline physiological saline
- the measurement items were core body temperature, blood pressure, heart rate and expiratory gas metabolism.
- Exercise economy was calculated from the obtained oxygen and carbon dioxide intake.
- Orotic acid used a free form (free form). Changes in core body temperature are shown in FIG. 5, changes in heart rate are shown in FIG. 6, and changes in heat production are shown in FIG. Figure 8 shows the exercise economy.
- intraperitoneal administration of 300 mg/kg orotic acid enhanced exercise economy, decreased heat production, and suppressed excessive core body temperature rise during exercise. From these results, it was found that orotic acid may improve endurance performance by suppressing the rise in core body temperature and extending the time for core body temperature to reach 40°C. In fact, the heart rate during exercise, which is an index of relative strength in endurance exercise, showed a significant decrease as shown in FIG. It was found that there is a possibility that it may have the effect of making it relatively easier. From the results of this example, it was clarified that orotic acid has the effect of enhancing exercise economy and suppressing the increase in core body temperature during exercise.
- Body temperature lowering agent body temperature lowering food composition, body temperature rise inhibitor, and body temperature lowering agent containing as an active ingredient at least one substance selected from the group consisting of orotic acid, derivatives thereof, and salts thereof of the present invention
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
本願は、2021年2月15日に、日本に出願された特願2021-21815号に基づき優先権を主張し、その内容をここに援用する。
[1] オロト酸、その誘導体、及び、それらの塩からなる群から選択される少なくとも1つの物質を有効成分として含有する、体温低下剤。
[2] 前記体温が、深部体温である、[1]に記載の体温低下剤。
[3] 前記オロト酸が、オロト酸フリー体である、[1]又は[2]に記載の体温低下剤。
[4] オロト酸、その誘導体、及び、それらの塩からなる群から選択される少なくとも1つの物質を有効成分として含有する、体温上昇抑制剤。
[5] 前記体温が、深部体温である、[4]に記載の体温上昇抑制剤。
[6] 前記オロト酸が、オロト酸フリー体である、[4]又は[5]に記載の体温上昇抑制剤。
[7] オロト酸、その誘導体、及び、それらの塩からなる群から選択される少なくとも1つの物質を有効成分として含有する、体温低下用食品組成物。
[8] オロト酸、その誘導体、及び、それらの塩からなる群から選択される少なくとも1つの物質を有効成分として含有する、体温上昇抑制用食品組成物。
[9] 前記体温が、深部体温である、[7]又は[8]に記載の食品組成物。
[10] 前記オロト酸が、オロト酸フリー体である、[7]~[9]のいずれか一項に記載の食品組成物。
本発明の体温低下剤は、オロト酸、その誘導体、及び、それらの塩(以下、これらを総称して「オロト酸類」と称する場合がある)からなる群から選択される少なくとも1つの物質を有効成分として含有する。
本発明の体温上昇抑制剤は、オロト酸類からなる群から選択される少なくとも1つの物質を有効成分として含有する。
また、本発明の体温低下剤は、安静時の体温を低下させるが、体に対し健康な状態を維持できるため、例えば、健康な状態を維持しつつ、体温上昇を抑制する必要がある場合において利用することができる。さらに、将来的には、冬眠や寿命を延ばすことにも応用が可能と期待される。
TRM54Pラット用テレメトリーシステム(KAHA Sciences社製)およびSmartPad(TR181:KAHA Science社製)を用いて安静時の深部体温を測定し、数値化する。TRM54Pラット用テレメトリーシステムの本体を被験動物の腹腔内に留置し、測定を行う。実験はすべて明期に行い、実験日当日は、試験開始2時間前にラットを絶食におくことで食餌による熱産生の影響を排除する。安静時の深部体温を20分間測定した後、薬剤(オロト酸類)またはVehicleを腹腔内投与し、120分間深部体温の測定を行う。
安静時の深部体温が、オロト酸類を投与しない場合と比較して低下する場合、体温低下作用を有すると判定することができる。
ラットを10°の傾斜を設けた小動物用レッドミル代謝チャンバーに入れ、20分間の安静時深部体温の測定を行った後、腹腔内に薬剤(オロト酸類)を単回投与する。投与後15分間安静状態に置き、運動を開始する。運動は5m/minの走速度で開始し、5分間かけて20m/minまで増加させ、上記安静時の深部体温の測定方法と同様にして深部体温の測定を行う。
運動時の深部体温が、オロト酸類を投与しない場合と比較して抑制される場合、体温上昇抑制作用を有すると判定することができる。
オロト酸類は、体温低下作用を有するため、安静時の体温を低下させる場合における体温低下用食品組成物の有効成分として各種食品組成物に含有させることができる。本発明において、食品組成物には、食品だけでなく飲料も含む。
[実施例1](オロト酸による安静時の深部体温に対する効果)
10週齢Wistar系雄性ラットを用い、実験日までに1週間の予備飼育期間を設けた。実験時の室温は室内温度22±2℃を維持した。
予備飼育後に体温を測定するテレメトリー(TRM54P、KAHA Sciences社製)を腹腔内に留置し、回復期間と馴化期間を1週間ずつ設けた。オロト酸300mg/kg、又はオロト酸30mg/kg、Vehicle(1%カルボキシルメチルセルロース)を腹腔内投与し、安静時の深部体温に及ぼす効果を検討した。測定は深部体温及び心拍数に併せて、呼気ガス分析機(商品名:オキシマックス等流量システム、Columbus instruments社製)を用いて酸素・二酸化炭素摂取量を測定し、呼吸交換比(respiratory exchange ratio、RERとも称する)および熱産生量を算出した。また、赤外線ビームセンサー(商品名:ビームセンサー式自発運動量測定装置、Panlab社製)を用いて自発活動量を測定した。
本実施例の結果から、オロト酸は熱産生を抑制し、深部体温を低下させる効果を有することが明らかになった。
10週齢Wistar系雄性ラットを用い、実験日までに1週間の予備飼育期間を設けた。実験時の室温は室内温度22±2℃を維持した。
予備飼育後に体温を測定するテレメトリー(商品名:TRM54P、KAHA Sciences社製)を腹腔内に留置し、1週間の回復期間後に走行試験を行った。
本実施例の結果から、オロト酸は運動経済性を高め、運動時の深部体温上昇を抑制する効果を有することが明らかとなった。
Claims (10)
- オロト酸、その誘導体、及び、それらの塩からなる群から選択される少なくとも1つの物質を有効成分として含有する、体温低下剤。
- 前記体温が、深部体温である、請求項1に記載の体温低下剤。
- 前記オロト酸が、オロト酸フリー体である、請求項1又は2に記載の体温低下剤。
- オロト酸、その誘導体、及び、それらの塩からなる群から選択される少なくとも1つの物質を有効成分として含有する、体温上昇抑制剤。
- 前記体温が、深部体温である、請求項4に記載の体温上昇抑制剤。
- 前記オロト酸が、オロト酸フリー体である、請求項4又は5に記載の体温上昇抑制剤。
- オロト酸、その誘導体、及び、それらの塩からなる群から選択される少なくとも1つの物質を有効成分として含有する、体温低下用食品組成物。
- オロト酸、その誘導体、及び、それらの塩からなる群から選択される少なくとも1つの物質を有効成分として含有する、体温上昇抑制用食品組成物。
- 前記体温が、深部体温である、請求項7又は8に記載の食品組成物。
- 前記オロト酸が、オロト酸フリー体である、請求項7~9のいずれか一項に記載の食品組成物。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/276,762 US20240122929A1 (en) | 2021-02-15 | 2022-02-14 | Body temperature lowering agent, body temperature elevation suppressor, food composition for lowering body temperature,and food composition for suppressing body temperature elevation |
JP2022580713A JPWO2022173047A1 (ja) | 2021-02-15 | 2022-02-14 | |
CN202280013786.3A CN116847849A (zh) | 2021-02-15 | 2022-02-14 | 体温降低剂、体温上升抑制剂、体温降低用食品组合物和体温上升抑制用食品组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-021815 | 2021-02-15 | ||
JP2021021815 | 2021-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022173047A1 true WO2022173047A1 (ja) | 2022-08-18 |
Family
ID=82838374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/005738 WO2022173047A1 (ja) | 2021-02-15 | 2022-02-14 | 体温低下剤、体温上昇抑制剤、体温低下用食品組成物、及び体温上昇抑制用食品組成物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240122929A1 (ja) |
JP (1) | JPWO2022173047A1 (ja) |
CN (1) | CN116847849A (ja) |
WO (1) | WO2022173047A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012126683A (ja) * | 2010-12-16 | 2012-07-05 | Kirin Holdings Co Ltd | 交感神経活性化用組成物 |
JP2012246280A (ja) * | 2011-05-31 | 2012-12-13 | Kirin Holdings Co Ltd | 酸素消費量及びエネルギー消費量の低減剤 |
WO2018207929A1 (ja) * | 2017-05-12 | 2018-11-15 | 株式会社古川リサーチオフィス | 動脈血中酸素飽和度の向上剤 |
WO2020091014A1 (ja) * | 2018-11-02 | 2020-05-07 | 株式会社古川リサーチオフィス | 心拍数低下剤 |
WO2020218148A1 (ja) * | 2019-04-23 | 2020-10-29 | 株式会社古川リサーチオフィス | 過酸化脂質生成抑制剤 |
-
2022
- 2022-02-14 WO PCT/JP2022/005738 patent/WO2022173047A1/ja active Application Filing
- 2022-02-14 US US18/276,762 patent/US20240122929A1/en active Pending
- 2022-02-14 CN CN202280013786.3A patent/CN116847849A/zh active Pending
- 2022-02-14 JP JP2022580713A patent/JPWO2022173047A1/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012126683A (ja) * | 2010-12-16 | 2012-07-05 | Kirin Holdings Co Ltd | 交感神経活性化用組成物 |
JP2012246280A (ja) * | 2011-05-31 | 2012-12-13 | Kirin Holdings Co Ltd | 酸素消費量及びエネルギー消費量の低減剤 |
WO2018207929A1 (ja) * | 2017-05-12 | 2018-11-15 | 株式会社古川リサーチオフィス | 動脈血中酸素飽和度の向上剤 |
WO2020091014A1 (ja) * | 2018-11-02 | 2020-05-07 | 株式会社古川リサーチオフィス | 心拍数低下剤 |
WO2020218148A1 (ja) * | 2019-04-23 | 2020-10-29 | 株式会社古川リサーチオフィス | 過酸化脂質生成抑制剤 |
Also Published As
Publication number | Publication date |
---|---|
CN116847849A (zh) | 2023-10-03 |
JPWO2022173047A1 (ja) | 2022-08-18 |
US20240122929A1 (en) | 2024-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220105117A1 (en) | Compositions comprising nicotinamide riboside and a urolithin | |
EP2139466A2 (en) | Magnesium compositions and uses thereof | |
US20220241229A1 (en) | Methods and Compositions for Altering Senescence Associated Secretory Phenotype | |
JP2010521420A (ja) | 健康増進剤製造のための、ベタインおよび/またはコリンと組み合わせたグアニジノ酢酸(塩)の使用 | |
JP5788715B2 (ja) | 酸素消費量及びエネルギー消費量の低減剤 | |
WO2022173047A1 (ja) | 体温低下剤、体温上昇抑制剤、体温低下用食品組成物、及び体温上昇抑制用食品組成物 | |
JP5281268B2 (ja) | 筋力向上剤 | |
CN111372586B (zh) | 包含chp的骨丢失疾病的预防、改善或治疗用组合物 | |
TWI733817B (zh) | 睡眠改善劑 | |
KR101875705B1 (ko) | 디아미노디페닐술폰을 포함하는 근육 소모 관련 질환의 예방 또는 치료용 약학적 조성물 | |
JP7162917B2 (ja) | 心拍数低下剤 | |
JP5394644B2 (ja) | アスペルロシドまたはその類縁体を含む筋肉増強剤 | |
WO2007001006A1 (ja) | 重金属障害改善剤およびそれを含有する医薬組成物、食品、化粧料 | |
JP2015214518A (ja) | 睡眠の質を改善する方法及び睡眠の質の改善用の経口用組成物 | |
WO2017159741A1 (ja) | 行動体力向上剤 | |
WO2000024422A1 (fr) | Procede de production de regulateurs glycolytiques du metabolisme | |
US20220218793A1 (en) | Use of composition for preventing, ameliorating, or treating bone loss disorders, comprising cyclo-hispro (chp) and parathyroid hormone | |
JP2006516030A (ja) | Copd及びその他の疾患に罹患した患者の状態を改善するための組成物及び方法 | |
WO2024029620A1 (ja) | 脳血流量増加剤、脳活動促進剤及び覚醒度向上剤 | |
JP2006137746A (ja) | オレキシン誘導組成物 | |
WO2014163151A1 (ja) | 酵母培養物及び内服組成物 | |
JP2019099488A (ja) | ペプチド及びその利用 | |
JP2015214516A (ja) | 活力及び/又は集中力向上剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22752869 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280013786.3 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022580713 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22752869 Country of ref document: EP Kind code of ref document: A1 |